ArticleMedicine2026
Alarin as a potential biomarker in childhood obesity: Evidence from a case-control study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies on Alarin, a newly identified orexigenic adipokine, have mainly focused on adults, while research investigating Alarin levels and its association with obesity in children remains limited. The aim of this study was to measure Alarin levels in children and adolescents with obesity and investigate their relationship with various metabolic parameters, as well as explore how these associations may differ by age group and gender. This prospective case-control study included 30 children with obesity (body mass index [BMI] standard deviation score [SDS] > +2) and 49 age- and gender-matched controls (BMI SDS between -1.9 and +1.9). Participants were recruited at the pediatric endocrinology outpatient clinic between April 2022 and April 2023. Clinical data, including chronological age, physical examination findings, and laboratory test results (alanine transaminase [ALT], aspartate transaminase [AST], total cholesterol, triglycerides, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], fasting blood glucose, and insulin levels), were collected from the hospital's information management system. The presence and severity of hepatosteatosis were assessed by abdominal ultrasound. Insulin resistance (IR) was determined using the HOMA-IR index, with a cutoff value of 2.5 for prepubertal patients and 3.16 for pubertal patients. The mean age of the participants was 11.6 ± 3.5 years (range: 4.5-17.7 years), with 58.2% (n = 46) being female. Serum Alarin, LDL-C, γ-glutamyl transferase (GGT), insulin, and HOMA-IR levels were significantly higher in the obesity group (P < .05). In the obese group, Alarin levels showed positive correlations with age, BMI SDS, fasting glucose, and presence of hepatic steatosis (P < .05). No significant correlations were found in the control group. The study found elevated Alarin levels in children and adolescents with obesity, similar to previous findings in adults. This suggests that Alarin may play a role in energy homeostasis and insulin resistance in childhood obesity. The results contribute to a deeper understanding of obesity's molecular mechanisms of obesity and may help to identify new therapeutic targets for preventing obesity-related complications and metabolic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.